IN FOCUS: Nanobiotix CEO Laurent Levy explains the many benefits of nanomedicine

5 January 2015

Nanotechnology is poised to become the ‘next big thing’ in global health care. While big pharma companies clamor to partner with small biotech firms developing nanotech solutions, French nanomedicine company Nanobiotix (Euronext: NANO–ISIN) is already at the forefront of nanotechnology. Its NanoXray platform, which enhances radiotherapy for the local treatment of cancer, is already making waves in oncology.

Chief executive Laurent Levy, who is also the co-founder and president of the executive board and vice chair for the European Technology Platform on Nanomedicine, spoke to The Pharma Letter about the company’s aims and the scope of nanomedicine.

The Pharma Letter: Nanobiotix announced last month the completion of a private placement with Capital Ventures International of new shares with warrants attached for a total amount of 10,393,500 euros ($12.7 million). What will this financing allow you to do?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK